The Licensing Executives Society (USA and Canada) named five licensing deals as its 2018 Deals of Distinction at its 2018 Annual Meeting in Boston this month.
The winning deal in the life sciences sector was between Pieris Pharmaceuticals and AstraZeneca, who cooperated on the preclinical development of antibody mimics to treat respiratory diseases. In the energy, chemicals and materials sector, LES recognized the partnership between Lightbridge and Framatome in the commercialization of nuclear fuel technology. The high technology sector recognized Blockstack’s US$50 million initial coin offering.